Smead Capital Management INC Increased Its Amgen INC (AMGN) Stake by $10.28 Million; Shares Declined

June 27, 2018 - By Jeanette Garcia

Amgen Inc. (NASDAQ:AMGN) Corporate LogoBig Money Sentiment decreased to 0.88 in 2018 Q1. It has change of 0.34, from 2017Q4’s 1.22. The ratio turned negative due to AMGN positioning: 67 sold and 557 reduced. 114 funds bought stakes and 435 increased stakes. Investors holded 551.71 million in 2017Q4 but now own 502.72 million shares or 8.88% less. Pennsylvania Tru invested in 0.76% or 96,495 shs. Td Asset Mgmt Inc holds 0.14% or 545,671 shs in its capital. Woodstock reported 0.28% stake. South Texas Money Mgmt Limited owns 206,705 shs or 1.61% of their US capital. First Western Cap Mgmt Company holds 2.44% or 3,023 shs. Caxton Lp reported 0.02% of its capital in Amgen Inc. (NASDAQ:AMGN). Peregrine Asset Advisers has invested 0.24% in Amgen Inc. (NASDAQ:AMGN). Lombard Odier Asset (Europe) Limited has invested 0.08% of its capital in Amgen Inc. (NASDAQ:AMGN). Eagle Ridge Mngmt has invested 0.09% in Amgen Inc. (NASDAQ:AMGN). Factory Mutual Ins owns 87,250 shs. Union Bancshares reported 1,893 shs. Nadler Group reported 0.08% stake. London Of Virginia owns 1,535 shs or 0% of their US capital. Savings Bank Of America Corporation De stated it has 9.18 million shs. Mai Cap has 0.69% invested in Amgen Inc. (NASDAQ:AMGN) for 71,465 shs.

AMGN registered $1.65 million net activity with 0 insider purchases and 6 insider sales since January 16, 2018.

In 2018Q1 SEC form is reported Smead Capital Management Inc’s stake in Amgen Inc (AMGN) which was rose by 8.86%. The company’s stock declined 5.44% with the market as Smead Capital Management Inc bought 60,444 shares. The biological products (no diagnostic substances) company reported $126.59M value for the 2018Q1. Now the institutional investor is holding 742,558 shares, compared to the 682,114 from the previous quarter. Smead Capital Management Inc has cut its stake in Paypal Hldgs Inc and also reduced its holding in Ebay Inc (NASDAQ:EBAY) by 536,722 shares in the quarter, for a total of 2.12 million shares.

For more Amgen Inc. (NASDAQ:AMGN) news announced briefly go to: Seekingalpha.com, Fool.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Amgen Should Rebound On Aimovig And Kyprolis Revenue” announced on June 20, 2018, “Long-Term Investors Take Note — These 5 Big Pharma Companies Have the Best Pipelines” on June 24, 2018, “Amgen Has Me Worried Therefore Selling Calls” with a publish date: May 31, 2018, “EC grants full approval for Amgen’s Blincyto” and the last “The Best Dividend-Paying Biotech Stocks For Your Portfolio” with publication date: June 25, 2018.

Amgen Inc. (NASDAQ:AMGN) Ratings Coverage

Total analysts of 13 have positions in Amgen Inc (NASDAQ:AMGN) as follows: 6 rated it a “Buy”, 0 with “Sell” and 7 with “Hold”. The positive are 46%. The firm has $220 highest while $180 is the lowest price target. The average target $196.18 is 6.28% above the last ($184.59) price. Since January 9, 2018 according to StockzIntelligence Inc Amgen Inc has 16 analyst reports. On Thursday, April 5 the firm earned “Equal-Weight” rating by Barclays Capital. The company rating was maintained by Piper Jaffray on Thursday, January 18. On Wednesday, April 25 the stock of Amgen Inc. (NASDAQ:AMGN) earned “Overweight” rating by Morgan Stanley. In Thursday, February 1 report Piper Jaffray maintained it with “Buy” rating and $190.0 target. On Monday, January 22 the rating was maintained by RBC Capital Markets with “Hold”. In Wednesday, January 24 report JP Morgan maintained the stock with “Neutral” rating. On Thursday, February 1 the stock has “Buy” rating by Cowen & Co. On Monday, February 12 Mizuho maintained the shares of AMGN in report with “Buy” rating. On Friday, February 2 the rating was maintained by Morgan Stanley with “Overweight”. On Friday, February 2 the firm has “Neutral” rating by Credit Suisse given.

Amgen Inc. (NASDAQ:AMGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.